HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Neutral rating on Sage Therapeutics while lowering the price target from $25 to $14.
October 30, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained a Neutral rating on Sage Therapeutics and lowered the price target from $25 to $14, indicating a less optimistic outlook.
The reduction in the price target from $25 to $14 by HC Wainwright & Co. suggests a less favorable view on Sage Therapeutics' future performance, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100